CLINICAL TRIALS AND OBSERVATIONS Differentiation syndrome in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and anthracycline chemotherapy: characteristics, outcome, and prognostic factors

نویسندگان

  • Pau Montesinos
  • Juan M. Bergua
  • Edo Vellenga
  • Chelo Rayón
  • Ricardo Parody
  • Javier de la Serna
  • Angel León
  • Jordi Esteve
  • Gustavo Milone
  • Guillermo Debén
  • Concha Rivas
  • Marcos González
  • Mar Tormo
  • Joaquín Díaz-Mediavilla
  • Jose D. González
  • Silvia Negri
  • Miguel A. Sanz
چکیده

1Hospital Universitario La Fe, Valencia, Spain; 2Department of Medicine of the Universitat Autònoma de Barcelona, Barcelona, Spain; 3Hospital San Pedro de Alcántara, Cáceres, Spain; 4University Hospital, Groningen, The Netherlands; 5Hospital Central de Asturias, Oviedo, Spain; 6Hospital Universitario Virgen del Rocío, Sevilla, Spain; 7Hospital 12 de Octubre, Madrid, Spain; 8Hospital General, Jerez de la Frontera, Spain; 9Hospital Clinic, Barcelona, Spain; 10Fundaleu, Buenos Aires, Argentina; 11Hospital Juan Canalejo, La Coruña, Spain; 12Hospital General, Alicante, Spain; 13Hospital Universitario, Salamanca, Spain; 14Hospital Clínico Universitario, Valencia, Spain; 15Hospital Clínico San Carlos, Madrid, Spain; 16Hospital Insular, Las Palmas, Spain; 17Hospital Carlos Haya, Málaga, Spain; 18Hospital de Cruces, Baracaldo, Spain; 19Hospital Sant Pau, Barcelona, Spain; and 20Erasmus University Medical Center, Rotterdam, The Netherlands

برای دانلود رایگان متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید

ثبت نام

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

منابع مشابه

CLINICAL OBSERVATIONS, INTERVENTIONS, AND THERAPEUTIC TRIALS Treatment of newly diagnosed and relapsed acute promyelocytic leukemia with intravenous liposomal all-trans retinoic acid

A novel intravenous liposomal formulation of all-trans retinoic acid (ATRA) was evaluated in 69 patients with acute promyelocytic leukemia (APL): 32 new diagnoses, 35 relapses, and 2 oral ATRA failures. Liposomal ATRA (90 mg/m2) was administered every other day until complete remission (CR) or a maximum of 56 days. Treatment following CR was liposomal ATRA with or without chemotherapy. In an in...

متن کامل

Maintenance therapy with all-trans retinoic acid and arsenic trioxide improves relapse-free survival in adults with low- to intermediate-risk acute promyelocytic leukemia who have achieved complete remission after consolidation therapy

BACKGROUND Currently, the optimal maintenance therapy for patients with acute promyelocytic leukemia (APL) who have achieved complete remission (CR) after completing consolidation chemotherapy remains controversial. The comparative effectiveness of the all-trans retinoic acid (ATRA) plus arsenic trioxide (As2O3) maintenance strategy with classic ATRA plus chemotherapy has not been evaluated. In...

متن کامل

CLINICAL OBSERVATIONS, INTERVENTIONS, AND THERAPEUTIC TRIALS Quantitative real-time RT-PCR analysis of PML-RAR mRNA in acute promyelocytic leukemia: assessment of prognostic significance in adult patients from intergroup protocol 0129

The potential prognostic value of quantitative real-time reverse transcription– polymerase chain reaction (RT-PCR [qrtPCR]) measurements of PML-RAR mRNA in acute promyelocytic leukemia was retrospectively assessed before treatment and at 3 posttreatment intervals in 123 patients on intergroup protocol 0129. The primary measure was the PMLRAR GAPDH normalized quotient (NQ), that is, PML-RAR mRNA...

متن کامل

Retinoic Acid: Result of the Randomized MRC Trial Trans Predict Prognosis in Acute Promyelocytic Leukemia Treated With All- Presenting White Blood Cell Count and Kinetics of Molecular Remission

http://bloodjournal.hematologylibrary.org/content/93/12/4131.full.html Updated information and services can be found at: (3667 articles) Clinical Trials and Observations • Articles on similar topics can be found in the following Blood collections http://bloodjournal.hematologylibrary.org/site/misc/rights.xhtml#repub_requests Information about reproducing this article in parts or in its entiret...

متن کامل

CLINICAL TRIALS AND OBSERVATIONS Role of minimal residual disease monitoring in acute promyelocytic leukemia treated with arsenic trioxide in frontline therapy

Data on minimal residual disease (MRD) monitoring in acute promyelocytic leukemia (APL) are available only in the context of conventional all-trans retinoic acid plus chemotherapy regimens. It is recognized that the kinetics of leukemia clearance is different with the use of arsenic trioxide (ATO) in the treatment of APL. We undertook a prospective peripheral blood RT-PCR–based MRD monitoring s...

متن کامل

ذخیره در منابع من

ذخیره در منابع من قبلا به منابع من ذحیره شده

{@ msg_add @}


  با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید

عنوان ژورنال:

دوره   شماره 

صفحات  -

تاریخ انتشار 2009